MC
ALXN

Moors & Cabot’s Alexion Pharmaceuticals ALXN Stock Holding History

Moors & Cabot’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,214
Closed -$502K – 847
2020
Q4 		$502K Buy
3,214
+714
+29% +$91.8K 0.04% 366
2020
Q3 		$286K Buy
+2,500
New +$270K 0.03% 482

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Moors & Cabot's ALXN Position: Q1 2021 in Review

Moors & Cabot sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 3,214 shares — an estimated $502K sold.

Moors & Cabot first reported a position in ALXN in Q3 2020 and held it in 2 quarters. The position peaked at $502K in Q4 2020. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Moors & Cabot reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Moors & Cabot sold 3,214 Alexion Pharmaceuticals shares in Q1 2021, an estimated $502K.
  • Moors & Cabot first reported a position in Alexion Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Moors & Cabot's Alexion Pharmaceuticals position peaked at $502K in Q4 2020.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Moors & Cabot's 13F filing for Q1 2021, filed 12 May 2021.